187 related articles for article (PubMed ID: 19442208)
21. Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.
Vink S; Alewood PF
Br J Pharmacol; 2012 Nov; 167(5):970-89. PubMed ID: 22725651
[TBL] [Abstract][Full Text] [Related]
22. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain.
Winquist RJ; Pan JQ; Gribkoff VK
Biochem Pharmacol; 2005 Aug; 70(4):489-99. PubMed ID: 15950195
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis and Biological Evaluation of Two Opioid Agonist and Cav 2.2 Blocker Multitarget Ligands.
Mollica A; Costante R; Novellino E; Stefanucci A; Pieretti S; Zador F; Samavati R; Borsodi A; Benyhe S; Vetter I; Lewis RJ
Chem Biol Drug Des; 2015 Aug; 86(2):156-62. PubMed ID: 25393330
[TBL] [Abstract][Full Text] [Related]
24. omega-conotoxin GVIA alters gating charge movement of N-type (CaV2.2) calcium channels.
Yarotskyy V; Elmslie KS
J Neurophysiol; 2009 Jan; 101(1):332-40. PubMed ID: 18971294
[TBL] [Abstract][Full Text] [Related]
25. L-Cysteine based N-type calcium channel blockers: structure-activity relationships of the C-terminal lipophilic moiety, and oral analgesic efficacy in rat pain models.
Seko T; Kato M; Kohno H; Ono S; Hashimura K; Takenobu Y; Takimizu H; Nakai K; Maegawa H; Katsube N; Toda M
Bioorg Med Chem Lett; 2002 Sep; 12(17):2267-9. PubMed ID: 12161113
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers.
Seko T; Kato M; Kohno H; Ono S; Hashimura K; Takimizu H; Nakai K; Maegawa H; Katsube N; Toda M
Bioorg Med Chem Lett; 2001 Aug; 11(16):2067-70. PubMed ID: 11514140
[TBL] [Abstract][Full Text] [Related]
27. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
Miljanich GP
Curr Med Chem; 2004 Dec; 11(23):3029-40. PubMed ID: 15578997
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and preliminary pharmacological evaluation of 4-aminopiperidine derivatives as N-type calcium channel blockers active on pain and neuropathic pain.
Teodori E; Baldi E; Dei S; Gualtieri F; Romanelli MN; Scapecchi S; Bellucci C; Ghelardini C; Matucci R
J Med Chem; 2004 Nov; 47(24):6070-81. PubMed ID: 15537361
[TBL] [Abstract][Full Text] [Related]
29. Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model.
Son WS; Jeong KS; Lim SM; Pae AN
Bioorg Med Chem Lett; 2019 May; 29(10):1168-1172. PubMed ID: 30928197
[TBL] [Abstract][Full Text] [Related]
30. Design and biological evaluation of non-peptide analogues of omega-conotoxin MVIIA.
Menzler S; Bikker JA; Suman-Chauhan N; Horwell DC
Bioorg Med Chem Lett; 2000 Feb; 10(4):345-7. PubMed ID: 10714496
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the substituted N-triazole oxindole TROX-1, a small-molecule, state-dependent inhibitor of Ca(V)2 calcium channels.
Swensen AM; Herrington J; Bugianesi RM; Dai G; Haedo RJ; Ratliff KS; Smith MM; Warren VA; Arneric SP; Eduljee C; Parker D; Snutch TP; Hoyt SB; London C; Duffy JL; Kaczorowski GJ; McManus OB
Mol Pharmacol; 2012 Mar; 81(3):488-97. PubMed ID: 22188924
[TBL] [Abstract][Full Text] [Related]
32. Small molecules targeting sodium and calcium channels for neuropathic pain.
Bear B; Asgian J; Termin A; Zimmermann N
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):543-61. PubMed ID: 19562650
[TBL] [Abstract][Full Text] [Related]
33. Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels.
Yamamoto T; Niwa S; Ohno S; Onishi T; Matsueda H; Koganei H; Uneyama H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M
Bioorg Med Chem Lett; 2006 Feb; 16(4):798-802. PubMed ID: 16309909
[TBL] [Abstract][Full Text] [Related]
34. Antisympathetic and hemodynamic property of a dual L/N-type Ca(2+) channel blocker cilnidipine in rats.
Takahara A; Koganei H; Takeda T; Iwata S
Eur J Pharmacol; 2002 Jan; 434(1-2):43-7. PubMed ID: 11755164
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity study of L-cysteine-based N-type calcium channel blockers: optimization of N- and C-terminal substituents.
Seko T; Kato M; Kohno H; Ono S; Hashimura K; Takimizu H; Nakai K; Maegawa H; Katsube N; Toda M
Bioorg Med Chem Lett; 2002 Mar; 12(6):915-8. PubMed ID: 11958993
[TBL] [Abstract][Full Text] [Related]
36. Electrophysiological characterization of activation state-dependent Ca(v)2 channel antagonist TROX-1 in spinal nerve injured rats.
Patel R; Rutten K; Valdor M; Schiene K; Wigge S; Schunk S; Damann N; Christoph T; Dickenson AH
Neuroscience; 2015 Jun; 297():47-57. PubMed ID: 25839150
[TBL] [Abstract][Full Text] [Related]
37. Evolving therapeutic indications for N-type calcium channel blockers: from chronic pain to alcohol abuse.
Belardetti F
Future Med Chem; 2010 May; 2(5):791-802. PubMed ID: 21426203
[TBL] [Abstract][Full Text] [Related]
38. SO-3, a new O-superfamily conopeptide derived from Conus striatus, selectively inhibits N-type calcium currents in cultured hippocampal neurons.
Wen L; Yang S; Qiao H; Liu Z; Zhou W; Zhang Y; Huang P
Br J Pharmacol; 2005 Jul; 145(6):728-39. PubMed ID: 15880145
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels.
Sairaman A; Cardoso FC; Bispat A; Lewis RJ; Duggan PJ; Tuck KL
Bioorg Med Chem; 2018 Jul; 26(11):3046-3059. PubMed ID: 29622412
[TBL] [Abstract][Full Text] [Related]
40. The influence exerted by the beta(3) subunit on MVIIA omega-conotoxin binding to neuronal N-type calcium channels.
Luchian T
Biochim Biophys Acta; 2001 Jun; 1512(2):329-34. PubMed ID: 11406110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
